Innogenetics receives unanimous verdict against Abbott
On Friday, September 1, 2006, a Jury unanimously upheld the validity of Innogenetics' patent, U.S. Patent No. 5,846,704 ("the '704 patent"), which claims a method of genotyping the hepatitis C Virus ("HCV"). The dispute began in September 2005 when Innogenetics brought suit against Abbott Laboratories alleging that Abbott was infringing its '704 patent. After the Court found Monday that Abbott's non-infringement argument was insufficient as a matter of law, the issue of the '704 patent's validity was tried to the Jury. After a four-day trial, the Jury began deliberations and shortly thereafter returned an unanimous verdict for Innogenetics that the '704 patent was valid in all its aspects. Last month, the Court issued a summary judgment decision denying Abbott's motion that the '704 patent is unenforceable.
The issues of damages and wilful infringement will begin being tried before the Jury next Tuesday. Shortly after the Jury's decision, Innogenetics also noted its intention to seek an injunction against Abbott.
Most read news
Other news from the department politics & laws
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Syrris Establish Japanese Subsidiary Office - Syrris Expand Global Sales Network to Match Growing Demand in the Far East
Sartorius reviews fiscal 2008 - Different outlook for the two Group divisions
SGS Australia opens new Sydney Laboratory for Environmental Testing
Thermo Fisher Scientific Announces Partnership with Megaware to Deliver New Bioequivalence Solution
Neandertal genome project reaches its goal - High-quality Neandertal genome provides novel insights into human origins
Opening the cavity floodgates - Biochemists investigate the transport of large proteins through bacterial cell membranes
Watermelon genome decoded - Decoded genome paves way for better watermelons
BIO White Paper Dispels Over-Patenting Myth - Patenting is a Critical Element in Fostering Research and Development
Dow acquires Rohm and Haas, creating world's leading specialty chemicals and advanced materials company - $18.8 billion transaction marks pivotal point in Dow's transformation
Cells stop dividing when this gene kicks into high gear